International Journal of Innovative Science and Research Technology (IJISRT),
Год журнала:
2024,
Номер
unknown, С. 2585 - 2591
Опубликована: Июнь 11, 2024
The
onset
of
Coronavirus
disease
2019
(COVID-19)
in
late
presented
a
severe
worldwide
health
crisis
with
widespread
morbidity
and
mortality.
Various
vaccine
platforms
have
been
rapidly
developed
approved
for
broad
use
swift
urgent
response
to
prevent
the
transmission
Severe
Acute
Respiratory
Syndrome
2
(SARS-CoV-2)
infection.
However,
these
vaccines
differ
significantly
terms
safety.
Heterologous
prime-boost
vaccination
enhances
safety
compared
homologous
vaccination,
although
it
could
lead
higher
cumulative
number
transient
adverse
events
reported
at
each
visit.
Therefore,
additional
strategies
are
necessary
improve
SARS-
CoV-2
Anecdotal
options
suggest
that
co-administration
can
reduce
effects
consequently,
avert
need
frequent
booster
doses.
This
study
reports
immunization
outcomes
against
SARS-CoV-2
virus
by
assessing
profiles
different
co-administered
BALB/c
mice.
Vaccine
combinations
comprising
mRNA/adenovirus26-vector,
mRNA/inactivated,
adenovirus26-vector/inactivated,
mRNA/adenovirus26-vector/inactivated
were
prepared
optimized
doses,
their
activities
upon
evaluated
comparison
individual
mRNA,
adenovirus26-vectored
inactivated
vaccines.
Twenty-eight
days
post-immunization,
various
treatments
through
hematological
biochemical
examination.
Importantly,
regimens
proved
safe
well-tolerated
mice,
as
evidenced
normal
values.
International Journal of Vaccine Theory Practice and Research,
Год журнала:
2024,
Номер
3(2), С. 1275 - 1344
Опубликована: Авг. 16, 2024
The
COVID-19
modified
mRNA
(modmRNA)
lipid
nanoparticle-based
“vaccines”
are
not
classical
antigen-based
vaccines
but
instead
prodrugs
informed
by
gene
therapy
technology.
Of
considerable
note,
these
products
have
been
linked
to
atypical
adverse
and
serious
event
profiles.
As
discussed
in
Part
1,
health-related
risks
drawbacks
were
drastically
misreported
underreported
the
Pfizer
Moderna
trial
evaluations
of
genetic
products.
Now
2,
we
examine
main
structural
functional
aspects
injectables.
modmRNA
injectable
introduce
a
unique
set
biological
challenges
human
body
with
potential
induce
an
extensive
range
adverse,
crippling,
life-threatening
effects.
Based
on
fact
that
there
is
no
current
method
quantify
host
(cell-based)
spike
protein
production
vivo
following
injection
prodrugs,
standard
“dose”.
This
part
due
differences
output,
which
depends
cell
metabolism
transfection
efficiency.
It
therefore
difficult
predict
profiles
individual
basis,
considering
millions
adults
across
world
reported
severe
events
context
products,
valid
concerns
raised
regarding
infants
younger
age
groups
for
whom
poses
only
minimal
risks.
We
address
process-related
impurities
inherent
mass
posed
contaminants.
then
categorize
principal
associated
brief
systems-based
synopsis
each
six
domains
harms:
(1)
cardiovascular,
(2)
neurological,
(3)
hematologic;
(4)
immunological,
(5)
oncological,
(6)
reproductive.
conclude
discussion
primary
public
health
regulatory
issues
arising
from
this
evidence-informed
synthesis
literature
reiterate
urgency
imposing
global
moratorium
modmRNA-LNP-based
platform.
International Journal of Molecular Sciences,
Год журнала:
2023,
Номер
24(6), С. 5312 - 5312
Опубликована: Март 10, 2023
Several
studies
report
elevated
blood
platelet
activation
and
altered
count
in
COVID-19
patients,
but
the
role
of
SARS-CoV-2
spike
protein
this
process
remains
intriguing.
Additionally,
there
is
no
data
that
anti-SARS-CoV-2
neutralizing
antibodies
(nAb)
may
attenuate
activity
toward
platelets.
Our
results
indicate
under
vitro
conditions,
increased
collagen-stimulated
aggregation
isolated
platelets
induced
binding
vWF
to
ristocetin-treated
blood.
The
also
significantly
reduced
collagen-
or
ADP-induced
decreased
GPIIbIIIa
(fibrinogen
receptor)
whole
blood,
depending
on
presence
anti-spike
nAb.
findings
suggest
activation/reactivity
patients
donors
vaccinated
with
and/or
previously-infected
should
be
supported
by
measurements
IgG
antibody
concentrations
International Journal of Innovative Science and Research Technology (IJISRT),
Год журнала:
2024,
Номер
unknown, С. 2585 - 2591
Опубликована: Июнь 11, 2024
The
onset
of
Coronavirus
disease
2019
(COVID-19)
in
late
presented
a
severe
worldwide
health
crisis
with
widespread
morbidity
and
mortality.
Various
vaccine
platforms
have
been
rapidly
developed
approved
for
broad
use
swift
urgent
response
to
prevent
the
transmission
Severe
Acute
Respiratory
Syndrome
2
(SARS-CoV-2)
infection.
However,
these
vaccines
differ
significantly
terms
safety.
Heterologous
prime-boost
vaccination
enhances
safety
compared
homologous
vaccination,
although
it
could
lead
higher
cumulative
number
transient
adverse
events
reported
at
each
visit.
Therefore,
additional
strategies
are
necessary
improve
SARS-
CoV-2
Anecdotal
options
suggest
that
co-administration
can
reduce
effects
consequently,
avert
need
frequent
booster
doses.
This
study
reports
immunization
outcomes
against
SARS-CoV-2
virus
by
assessing
profiles
different
co-administered
BALB/c
mice.
Vaccine
combinations
comprising
mRNA/adenovirus26-vector,
mRNA/inactivated,
adenovirus26-vector/inactivated,
mRNA/adenovirus26-vector/inactivated
were
prepared
optimized
doses,
their
activities
upon
evaluated
comparison
individual
mRNA,
adenovirus26-vectored
inactivated
vaccines.
Twenty-eight
days
post-immunization,
various
treatments
through
hematological
biochemical
examination.
Importantly,
regimens
proved
safe
well-tolerated
mice,
as
evidenced
normal
values.
